What is the recommended olmesartan dose range for adults, and how should it be adjusted in patients with moderate renal impairment (estimated glomerular filtration rate 30–59 mL/min/1.73 m²)?

Olmesartan Dose Range

The recommended olmesartan dose range for adults is 20-40 mg once daily, with a starting dose of 20 mg; no initial dose adjustment is required for patients with moderate renal impairment (eGFR 30-59 mL/min/1.73 m²), though these patients should be monitored closely as they have approximately doubled plasma concentrations compared to those with normal renal function. 1

Standard Adult Dosing

• Initial dose: 20 mg once daily 1
• Maximum dose: 40 mg once daily 1, 2
• Blood pressure-lowering effects are typically observed within 2 weeks, with maximum effects achieved by 8 weeks of treatment 2
• The medication demonstrates linear pharmacokinetics up to 80 mg in multiple-dose studies, with steady-state achieved within 3-5 days 1

Dosing in Moderate Renal Impairment (eGFR 30-59 mL/min/1.73 m²)

No initial dosage adjustment is recommended for patients with moderate renal impairment (creatinine clearance 20-40 mL/min). 1 However, critical considerations include:

• Patients with mild renal impairment (CrCl 40-59 mL/min) show up to 39% higher steady-state AUC and Cmax compared to healthy subjects 3
• Those with moderate impairment (CrCl 20-30 mL/min) demonstrate up to 82% higher plasma concentrations 3
• Despite these elevated concentrations, they remain several-fold lower than the well-tolerated 80 mg dose used in clinical trials 3
• The standard 20-40 mg daily dosing range can be used, as these increased concentrations are still within safe therapeutic limits 1, 3

Severe Renal Impairment Considerations

For context on the spectrum of renal dosing:

• Patients with severe renal impairment (CrCl <20 mL/min) should receive a lower starting dose, with a maximum of 20 mg daily 1, 3
• After repeated dosing, AUC is approximately tripled in severe renal impairment 1
• Renal clearance of olmesartan is 0.6 L/h, with 35-50% of absorbed dose recovered in urine 1

Clinical Efficacy in Renal Impairment

Studies demonstrate that olmesartan maintains antihypertensive efficacy across renal function categories:

• In elderly patients grouped by renal function, olmesartan 40 mg daily provided superior blood pressure control compared to ramipril in patients with normal/increased eGFR and mild eGFR reduction 4
• Normalization rates were comparable between treatment groups in patients with moderate-to-severe eGFR reduction (olmesartan 49.5% vs ramipril 46.3%) 4
• eGFR values did not show significant deterioration during olmesartan treatment across renal function categories 4

Important Caveats

• The FDA label explicitly states no initial dose adjustment is needed for moderate to marked renal impairment (CrCl <40 mL/min), but close monitoring is warranted 1
• Olmesartan shows modest accumulation with repeated dosing in patients with renal impairment, but this is accounted for in the standard dosing recommendations 3
• Food does not affect bioavailability; olmesartan can be administered with or without food 1
• Avoid combining with bile acid sequestrants like colesevelam, which reduces olmesartan AUC by 39%; if co-administration is necessary, give olmesartan at least 4 hours before colesevelam 1